Press Releases

SAN JOSE, Calif., Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed Paul Mendelman, MD as interim Chief Medical Offi

SAN FRANCISCO and SAN MATEO, Calif., Oct. 11, 2019 /PRNewswire/ -- Altais, in collaboration with Blue Shield of California, today announced a partnership with

OAKLAND, Calif., Oct. 11, 2019 /PRNewswire/ -- Alameda Health System (AHS) successfully launched its new Epic electronic health record (EHR) system last week. Epic is the most widely-used and comprehensive health records system in the country. The EHR implementation project started at AHS over three years ago as part of an effort to enhance care across the system, increa

LUND, Sweden, Oct. 11, 2019 /PRNewswire/ -- Hansa Biopharma will publish its interim report for the first nine months of 2019 at 8:00 a.m. CET on October 31, 2019. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business

OSAKA, Japan, Oct. 11, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (Head Office: Osaka; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. (Head Office:

SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted in the United States.

EDEN PRAIRIE, Minn., Oct. 10, 2019 /PRNewswire/ -- MIVI Neuroscience, Inc. today announced the appointment of Fred Moll, MD as Chairman of its Board of Directors. Dr. Moll has founded or co-founded multiple innovative medical device companies, and has served on numerous boards throughout his career. Dr. Moll is currently the Chi

SEOUL, South Korea, Oct. 10, 2019 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410: KOSDAQ) today announces that on Tuesday, October 8, 2019, Mezzion conducted the Type C meeting with the FDA in Silver Spring, Maryland. The purpose of the Type C meeting was to receive FDA guidance on Mezzion's NDA submi

PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak's anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with

VAUGHAN, ON, Oct. 10, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly upda